OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
72
Results
Show all
Save search
Copy query
Show results for
Unknown
(71)
Metabolomics
(1)
Repository
MetaboLights
(1)
Technology Type
Mass spectrometry
(1)
Instrument Platform
Q-Tof Premier (Waters)
(1)
Publication Date
2014
(1)
CHEBI ID
CHEBI:108517|CHEBI:108532
(1)
CHEBI:108633
(1)
CHEBI:108918
(1)
CHEBI:109146|CHEBI:109455
(1)
CHEBI:109896
(1)
CHEBI:127309
(1)
CHEBI:131458
(1)
CHEBI:131459
(1)
CHEBI:131460
(1)
CHEBI:131478
(1)
CHEBI:131976
(1)
CHEBI:131977
(1)
CHEBI:132770
(1)
CHEBI:132807
(1)
CHEBI:64423
(1)
CHEBI:64431
(1)
CHEBI:64433
(1)
CHEBI:64445
(1)
CHEBI:64446
(1)
CHEBI:64481
(1)
CHEBI:64483
(1)
CHEBI:64486
(1)
CHEBI:64487
(1)
CHEBI:64498
(1)
CHEBI:64504
(1)
CHEBI:64516
(1)
CHEBI:64517
(1)
CHEBI:64519
(1)
CHEBI:64520
(1)
CHEBI:64521
(1)
Metabolite Name
Cer(d18:1/17:0)
(1)
Cer(d18:1/22:6)
(1)
Custom adduct of 794,726 m/z - TG(46:1)
(1)
Custom adduct of 796,742 m/z - TG(14:0/16:0/16:0)+TG(16:0/18:0/12:0)
(1)
Custom adduct of 818,728 m/z - TG(48:3)
(1)
Custom adduct of 820,742 m/z - TG(48:2)
(1)
Custom adduct of 834,759 m/z - TG(49:2)
(1)
Custom adduct of 836,774 m/z - TG(49:1)
(1)
LysoPC(14:0)
(1)
LysoPC(16:0e)
(1)
LysoPC(16:1)
(1)
LysoPC(18:0)
(1)
LysoPC(18:1)
(1)
LysoPC(18:2)
(1)
LysoPC(18:3)
(1)
LysoPC(20:3)
(1)
LysoPC(20:4)
(1)
LysoPE(18:1)
(1)
LysoPE(18:2)
(1)
PC(30:0)
(1)
PC(32:0)
(1)
PC(32:0e)
(1)
PC(32:1)
(1)
PC(32:2)
(1)
PC(32:5)
(1)
PC(33:1)|PE(36:1)
(1)
PC(33:2)|PE(36:2)
(1)
PC(34:1)
(1)
PC(34:1e)|PE(37:1e)
(1)
PC(34:2)
(1)
Release Date
2021
(11)
2022
(10)
2020
(10)
2024
(8)
2019
(7)
2023
(6)
2018
(5)
2015
(5)
2017
(4)
2025
(2)
2012
(2)
2016
(1)
Previous
page
1 / 8
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
8
Next
page
Sort
by:
Relevance
Page size
10
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
Not available
S-EPMC6067803
|
biostudies-literature
Cite
Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients-Review and Perspectives.
Not available
S-EPMC10453164
|
biostudies-literature
Cite
New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development.
Not available
S-EPMC9400777
|
biostudies-literature
Cite
Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
Not available
S-EPMC4490921
|
biostudies-literature
Cite
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.
Not available
S-EPMC4569208
|
biostudies-literature
Cite
Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions.
Not available
S-EPMC6912467
|
biostudies-literature
Cite
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups.
Not available
S-EPMC8219718
|
biostudies-literature
Cite
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Not available
S-EPMC7794176
|
biostudies-literature
Cite
Beneficial Molecular Adaptations In BRCA-Mutation Carriers By Combined HIT/HIRT Intervention: Results From A Pilot Study.
Not available
S-EPMC7352264
|
biostudies-literature
Cite
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
Not available
S-EPMC5485412
|
biostudies-literature
Cite
Previous
page
1 / 8
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
8
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
